DDInter1544 DDInter1327
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Voriconazole
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Voriconazole